Vol.

No.

May 27, 2022May 27, 2022

DOWNLOAD THE PDF

What cancer centers need to do in the wake of Buffalo, Uvalde shootings

Cover Story

Free Guest Editorial

What cancer centers need to do in the wake of Buffalo, Uvalde shootings

By Candace S. Johnson

We hoped that our city might be “the last place this ever happened.”

Free Guest Editorial

Rob Winn on Buffalo massacre: “I grew up there. This is personal to me.”

By Robert A. Winn

Free Guest Editorial

Heartbreak in South Texas: Seeing the Uvalde killings through the lens of Mays Cancer Center

By Ruben A. Mesa

Wake Forest CCSG cut from 5 years to 3 as center changes leadership, administrative structure

By Paul Goldberg

Capitol Hill

House Republicans seek information on “me-too” drugs developed in China

By Alice Tracey

Capitol Hill

Cancer groups ask for $4.1 billion increase for NIH, $850 million boost for NCI in FY23

By Alice Tracey

Book Review Cancer History Project Free

Craig Jordan’s “Tamoxifen Tales” chronicles a pathbreaking scientific career

By Donald L. "Skip" Trump

Free In the Archives

Lovell Jones: “Bring forth survivors and make them visible”

In Brief

Koen van Besien named chief of Division of Hematology, director of Wesley Center for Immunotherapy at UH Seidman

Xiao-Jing Wang named chief science officer, associate director for basic science at UC Davis

William Gradishar, Shonta Chambers, Robert Winn, Hema Sundar receive NCCN 2022 awards

Abdul Rafeh Naqash receives SWOG/Hope Foundation Impact Award

SU2C establishes Lung Cancer Health Equity Research Team, SU2C Catalyst team

Clinical Roundup

SWOG researchers use cell-free DNA methylation to predict chemo benefit in bladder cancer

Roswell Park study: Targeting the E3 ligase activity of MDM2 could help control p53 protein

OSUCCC-James study: Selective dopamine D2 receptor agonists may curb cancer growth, with fewer side effects

Yale study supports use of metabolic therapy in breast cancer

IU cancer researchers refine colorectal cancer classification, identify therapeutic targets

Cedars-Sinai Cancer study shows hormone therapy + pelvic lymph node treatment improves survival in prostate cancer

Drugs & Targets

FDA approves Vidaza in newly diagnosed JMML

FDA grants marketing authorization to Parsortix System for liquid biopsy in MBC

FDA approves Tibsovo + Vidaza in IDH1-mutant newly diagnosed AML

Friends study: drugs that earn Breakthrough Therapy Designation at FDA provide maximum benefit in lung cancer

EMA adopts positive opinion for Keytruda in melanoma following complete resection

Case Western, Picture Health partner to develop AI tools for lung cancer

AmerisourceBergen establishes Clinical Trial Navigator tool to increase access to research opportunities

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

What cancer centers need to do in the wake of Buffalo, Uvalde shootings

Rob Winn on Buffalo massacre: “I grew up there. This is personal to me.”

Heartbreak in South Texas: Seeing the Uvalde killings through the lens of Mays Cancer Center

Wake Forest CCSG cut from 5 years to 3 as center changes leadership, administrative structure

House Republicans seek information on “me-too” drugs developed in China

Cancer groups ask for $4.1 billion increase for NIH, $850 million boost for NCI in FY23

Craig Jordan’s “Tamoxifen Tales” chronicles a pathbreaking scientific career

Lovell Jones: “Bring forth survivors and make them visible”

In Brief

Koen van Besien named chief of Division of Hematology, director of Wesley Center for Immunotherapy at UH Seidman

Xiao-Jing Wang named chief science officer, associate director for basic science at UC Davis

William Gradishar, Shonta Chambers, Robert Winn, Hema Sundar receive NCCN 2022 awards

Abdul Rafeh Naqash receives SWOG/Hope Foundation Impact Award

SU2C establishes Lung Cancer Health Equity Research Team, SU2C Catalyst team

Clinical Roundup

SWOG researchers use cell-free DNA methylation to predict chemo benefit in bladder cancer

Roswell Park study: Targeting the E3 ligase activity of MDM2 could help control p53 protein

OSUCCC-James study: Selective dopamine D2 receptor agonists may curb cancer growth, with fewer side effects

Yale study supports use of metabolic therapy in breast cancer

IU cancer researchers refine colorectal cancer classification, identify therapeutic targets

Cedars-Sinai Cancer study shows hormone therapy + pelvic lymph node treatment improves survival in prostate cancer

Drugs & Targets

FDA approves Vidaza in newly diagnosed JMML

FDA grants marketing authorization to Parsortix System for liquid biopsy in MBC

FDA approves Tibsovo + Vidaza in IDH1-mutant newly diagnosed AML

Friends study: drugs that earn Breakthrough Therapy Designation at FDA provide maximum benefit in lung cancer

EMA adopts positive opinion for Keytruda in melanoma following complete resection

Case Western, Picture Health partner to develop AI tools for lung cancer

AmerisourceBergen establishes Clinical Trial Navigator tool to increase access to research opportunities

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login